All In Biotech

Free tool

FAERS Monitor: Zevtera

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218275 or its brand name (Zevtera, Ceftobiprole Medocaril Sodium). Reports on generic versions are filed under their own applications.

Reports

57

Serious

55

96% of reports

Hospitalization

26

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use12
  • epilepsy10
  • torsade de pointes6
  • alveolar lung disease5
  • gangrene5
  • pneumonia necrotising5
  • rash5
  • agitation3
  • clostridium difficile infection3
  • diarrhoea3
  • pancytopenia3
  • pruritus3
  • pyrexia3
  • alanine aminotransferase increased2
  • anaemia2

Reports by year received

View as table
YearReports
20171
201810
20191
20211
20243
202519
202622

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,102 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
alveolar lung diseaseSignal59983.04268.939,359
pneumonia necrotisingSignal52876.71240.911,552
gangreneSignal5306.4132.61,231
torsade de pointesSignal6282.5132.51,413
epilepsySignal10120.768.81,072
clostridium difficile infectionSignal350.716.9101
pancytopeniaSignal319.86.637
agitationSignal315.15.027
alanine aminotransferase increased212.03.111
off label useSignal125.13.137
rashSignal54.21.810
anaemia23.91.02
pyrexia33.21.13
pruritus32.91.02
diarrhoea31.70.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.